期刊
NEUROLOGY
卷 76, 期 4, 页码 366-372出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e318208f4ab
关键词
-
资金
- Swedish Research Council [14002, 2006-6227, 2006-2740, 2006-3505]
- Alzheimer's Association [NIRG-08-90356]
- cNEUPRO
- Royal Swedish Academy of Sciences
- Sahlgrenska University Hospital
- Soderberg Foundation
- Gothenburg Medical Society
- Swedish Medical Society
- Swedish Brain Power
- Stiftelsen Gamla Tjanarinnor
- Lundbeck Foundation
- Gun och Bertil Stohnes stiftelse
- Ahlen-stiftelsen
- Swedish Brain Fund
- Alzheimer Foundation, Sweden
- Dementia Association, Sweden
- NIH Office of Rare Diseases
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Gamla Tjanarinnor
- Pfannenstills stiftelse
- Demensfonden
- Thureus stiftelse
- Anna-Lisa och Bror Bjornssons stiftelse
- Hjarnfonden
- Svenska Lakaresallskapet
- Neurologiskt handikappades riksforbund
- Goteborgs lakaresallskap
- Swedish Research Council
- Alzheimer's Association
- NIH/NICHD
- Ara Parseghian Medical Research Foundation
- Dana's Angels Research Trust
- NIH
- Ara Paseghian Medical Research Foundation
- Innogenetics
- Bristol-Myers Squibb
- Swedish Brain Power project
- Swedish Council for Working Life and Social Research
- Swedish Alzheimer Foundation
- Stiftelsen for Gamla Tjanarinnor
- King Gustaf V's and Queen Victoria's Foundation
Objective: Niemann-Pick disease type C (NPC) is an inherited disorder characterized by intracellular accumulation of lipids such as cholesterol and glycosphingolipids in endosomes and lysosomes. This accumulation induces progressive degeneration of the nervous system. NPC shows some intriguing similarities with Alzheimer disease (AD), including neurofibrillary tangles, but patients with NPC generally lack amyloid-beta (A beta) plaques. Lipids affect gamma-secretase-dependent amyloid precursor protein (APP) metabolism that generates A beta in vitro, but this has been difficult to prove in vivo. Our aim was to assess the effect of altered lipid constituents in neuronal membranes on amyloidogenic APP processing in humans. Methods: We examined A beta in CSF from patients with NPC (n = 38) and controls (n = 14). CSF was analyzed for A beta(38), A beta(40), A beta(42), alpha-cleaved soluble APP, beta-cleaved soluble APP, total-tau, and phospho-tau. Results: A beta release was markedly increased in NPC, with a shift toward the A beta(42) isoform. Levels of alpha(-) and beta-cleaved soluble APP were similar in patients and controls. Patients with NPC had increased total-tau. Patients on treatment with miglustat (n = 18), a glucosylceramide synthase blocker, had lower A beta(42) and total-tau than untreated patients. Conclusion: Increased CSF levels of A beta(38), A beta(40), and A beta(42) and unaltered levels of beta-cleaved soluble APP are consistent with increased gamma-secretase-dependent A beta release in the brains of patients with NPC. These results provide the first in vivo evidence that neuronal lipid accumulation facilitates gamma-secretase-dependent A beta production in humans and may be of relevance to AD pathogenesis. Neurology (R) 2011;76:366-372
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据